Header Logo

Connection

Arthur Krieg to Immunotherapy

This is a "connection" page, showing publications Arthur Krieg has written about Immunotherapy.
Connection Strength

0.542
  1. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med. 2003 Jul; 9(7):831-5.
    View in: PubMed
    Score: 0.182
  2. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009 Mar 28; 61(3):195-204.
    View in: PubMed
    Score: 0.067
  3. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005 Jan 01; 11(1):361-9.
    View in: PubMed
    Score: 0.050
  4. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep. 2004 Mar; 6(2):88-95.
    View in: PubMed
    Score: 0.048
  5. Baral RN, Saha A, Chatterjee S, Foon KA, Krieg A, Weiner GJ, Bhattacharya-Chatterjee M. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immunol Immunother. 2003 May; 52(5):317-27.
    View in: PubMed
    Score: 0.044
  6. Krieg AM. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev. 2001 Jun; 11(3):181-8.
    View in: PubMed
    Score: 0.039
  7. Krieg AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan; 6(1):23-7.
    View in: PubMed
    Score: 0.031
  8. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15; 89(8):2994-8.
    View in: PubMed
    Score: 0.030
  9. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007 Aug 15; 179(4):2493-500.
    View in: PubMed
    Score: 0.015
  10. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, Rasmussen WL, Krieg AM, Weiner GJ. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother. 2006 Sep-Oct; 29(5):558-68.
    View in: PubMed
    Score: 0.014
  11. Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM, Sandler AD. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg. 2006 Aug; 41(8):1361-8.
    View in: PubMed
    Score: 0.014
  12. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A. 1999 Jun 08; 96(12):6970-5.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.